Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0349 • ACR Convergence 2021
Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort
Jessica English¹, Dulaney Wilson², Gary Gilkeson², Jim Oates² and Diane Kamen², ¹Medical University of South Carolina, Johns Island, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Classification criteria for systemic lupus erythematosus (SLE) were recently published by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) to…
Abstract Number: 0534 • ACR Convergence 2021
Lymphatic Dysfunction in Murine Lupus Photosensitivity
William Ambler¹, Noa Schwartz², Jin Yeon Shin³, Rahgu Kataru⁴, Camila Carballo⁵, Scott Rodeo⁶, Babak Mehrara⁴ and Theresa Lu⁷, ¹Division of Pediatric Rheumatology, Department of Rheumatology, Hospital for Special Surgery. HSS Research Institute, Hospital for Special Surgery, New York, NY, ²Department of Medicine, Division of Rheumatology, Albert Einstein College of Medicine, New York, NY, ³Department of Surgery, Division of Plastic and Reconstructive Surgery Memorial Sloan Kettering, New York, NY, ⁴Department of Surgery, Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering, New York, NY, ⁵HSS Research Institute, Hospital for Special Surgery, New York, NY, ⁶HSS Research Institute, Hospital for Special Surgery; Department of Orthopedics, Hospital for Special Surgery, New York, NY, ⁷Hospital for Special Surgery, New York, NY
Background/Purpose: The lymphatic system is composed of vessels which carry fluid, soluble molecules, and cells from peripheral tissue to draining lymph nodes. Photosensitivity, an exaggerated…
Abstract Number: 0624 • ACR Convergence 2021
Validation of a Self-reported Measure of Extent and Reasons for Nonadherence in SLE
Kai Sun¹, Amanda Eudy², D. Ryan Anderson³, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Jennifer Rogers¹, Theresa Coles², Corrine Volis⁴ and Megan Clowse⁵, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is common in SLE and leads to increased hospitalizations, morbidity, and mortality. To better recognize nonadherence and address adherence barriers, there is…
Abstract Number: 0856 • ACR Convergence 2021
Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
Alexander Hall¹, Michael Trevisonno¹, Elizabeth Murray¹, Omoakhe Tisor¹, Emily Stanford¹, Jacob Gaines¹, Noor Anvery¹ and Ellen Ginzler², ¹SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: The risk of COVID-19 infection among patients with Systemic Lupus Erythematosus (SLE) is poorly understood. Patients with SLE often take medications which modulate the…
Abstract Number: 0873 • ACR Convergence 2021
Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study
Marcela Muñoz-Urbano¹, Julian Sanchez-Bautista², Yeison Santamaria-Alza¹, Diana C. Quintero-González³, Andres Ramirez², Adriana Lucía Vanegas-García⁴, Gloria M. Vasquez¹ and Luis Alonso Gonzalez³, ¹Rheumatology section, Universidad de Antioquia, Medellín, Colombia, ²Department of internal medicine, Universidad de Antioquia, Medellín, Colombia, ³Division of rheumatology, Universidad de Antioquia, Medellín, Colombia, ⁴Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia
Background/Purpose: Lupus enteritis (LE) is a potentially life-threatening manifestation of systemic lupus erythematosus (SLE), with an incidence ranging from 8% to 27%. Timely diagnosis is…
Abstract Number: 0890 • ACR Convergence 2021
Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index
Kichul Shin¹, In Ah Choi², Eunyoung Lee³, SE RIM CHOI⁴, Jina Yeo⁵, Yun Jong Lee⁶, Su-Jin Yoo⁷, Bong-Jin Hahm⁴, Jee Eun Park⁴, Ju Ho Lee⁸, Yeong-Wook Song⁴ and Ju Yeon Kim⁴, ¹Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Uijeongbu Eulji Medical Center, Seoul, South Korea, ⁴Seoul National University Hospital, Seoul, Republic of Korea, ⁵Gil Medical Center, Seoul, South Korea, ⁶Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea, ⁷Chungnam National University Hospital, Daejeon, Republic of Korea, ⁸Seoul National University Bundang Hospital, Yongin Si, Republic of Korea
Background/Purpose: Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index (SLICC-FI) is a novel health measure in systemic lupus erythematosus (SLE) and was reported to have impact…
Abstract Number: 1029 • ACR Convergence 2021
Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry
Allison Guttmann¹, Brendan Denvir¹, Jill Buyon², Martin Aringer³, H. Michael Belmont², Sara Sahl⁴, Jane Salmon⁵, Anca Askanase⁶, Joan Bathon⁷, Laura Geraldino⁸, Yousaf Ali⁹, Ellen Ginzler¹⁰, Chaim Putterman¹¹, Caroline Gordon¹², Charles Helmick¹³, Hilary Parton¹⁴ and Peter Izmirly¹, ¹New York University School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴UCLA-Harbor, Los Angeles, CA, ⁵Hospital for Special Surgery, New York, NY, ⁶Columbia University Medical Center, New York, NY, ⁷Columbia University, New York, NY, ⁸New York Presbyterian Hospital - Columbia Campus, New York, NY, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰SUNY Downstate Health Sciences University, Brooklyn, NY, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹³Centers for Disease Control and Prevention, Atlanta, GA, ¹⁴New York City Department of Health and Mental Hygiene, Long Island City, NY
Background/Purpose: The Manhattan Lupus Surveillance Program (MLSP) is a multi-racial/ethnic population-based registry with the primary goal to determine the prevalence and incidence of Systemic Lupus…
Abstract Number: L10 • ACR Convergence 2020
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
Victoria Werth¹, Jodi Karnell², William Rees², Nanette Mittereder³, Li Yan², Yanping Wu³, Jorn Drappa², Gabor Illei² and John Ratchford², ¹University of Pennsylvania, Philadelphia, PA, ²Viela Bio, Gaithersburg, MD, ³Viela Bio, Gaithersburg
Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…
Abstract Number: 0048 • ACR Convergence 2020
Determinants of Participation in Clinical Trials Among Patients with Lupus in the United States
Onengiya Harry¹, Carl Langefeld², Miranda Marion³, Trent Younts³, Lori Crosby⁴, Mara Vitolins³ and Avani Modi⁴, ¹Wake Forest School of Medicine, Clemmons, NC, ²Wake Forest School of Medicine, Winston Salem, NC, ³Wake Forest School of Medicine, Winston-Salem, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati
Background/Purpose: Patient and family participation in research is critical to improving health outcomes, and identifying factors that contribute to participation or lack of participation in…
Abstract Number: 0256 • ACR Convergence 2020
Patient Perspective of the Type 1 and 2 SLE Model: A Qualitative Study
Amanda Eudy¹, Amy Corneli², Kevin McKenna², Mithu Maheswaranathan¹, Bryce Reeve², David Pisetsky³ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: To better characterize the signs and symptoms of systemic lupus erythematosus (SLE) we have developed a conceptual model to characterize SLE activity into two dimensions: Type 1…
Abstract Number: 0273 • ACR Convergence 2020
Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
Jennifer Rogers¹, Megan Clowse², Lisa Criscione-Schreiber³, Jayanth Doss⁴, Rebecca Sadun⁴, Kai Sun⁵ and Amanda Eudy⁴, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University Hospital, Durham
Background/Purpose: Patients with SLE have poor health related quality of life (HRQoL), however the differences in the predominant causes of decreased HRQoL across subgroups of…
Abstract Number: 0291 • ACR Convergence 2020
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
Morgane Humbel¹, Florence Bellanger², Craig Fenwick², Alice Horisberger², Camillo Ribi² and Denis Comte², ¹CHUV, Lausanne, Vaud, Switzerland, ²CHUV, Lausanne, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by the production of autoantibodies. For this reason, anti-B cell therapy seems to be…
Abstract Number: 0433 • ACR Convergence 2020
Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus
Shivani Garg¹, Christie Bartels², Gaobin Bao³, Cristina Drenkard⁴ and S. Sam Lim³, ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ³Emory University, Atlanta, GA, ⁴Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: In the US, cardiovascular disease (CVD) is the leading cause of disparities in life expectancy between black and white populations. We recently reported a…
Abstract Number: 0570 • ACR Convergence 2020
The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus
Jennifer Ra¹, Jerik Leung², Elizabeth Baker² and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Saint Louis University, College for Public Health and Social Justice, St. Louis
Background/Purpose: The clinical variability of systemic lupus erythematosus (SLE) caused by the unpredictability of flares contributes to patients experiencing a diminished sense of social support.…
Abstract Number: 0837 • ACR Convergence 2020
Deletion of miR-223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Faslpr/lpr Mice
Sumie Hiramatsu Asano¹, Tomoyuki Mukai², Yoshitaka Morita³ and Jun Wada⁴, ¹Kawasaki Medical School/Department of Rheumatology, Kurashiki city, Japan, ²Kawasaki Medical School, Kurashiki-shi, Okayama, Japan, ³Kawasaki Medical School/Department of Rheumatology, Kurashiki, Okayama, Japan, ⁴Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences., Okayama city, Japan
Background/Purpose: To identify new candidate genes regulated by micro RNAs (miRNAs) and involved in the pathogenesis of systemic lupus erythematosus (SLE), we integrated miRNA and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].